Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$128.37 USD

128.37
1,778,973

+1.72 (1.36%)

Updated May 3, 2024 04:00 PM ET

After-Market: $128.34 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DexCom (DXCM) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.

Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio

by Zacks Equity Research

Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Is DexCom (DXCM) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

by Zacks Equity Research

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Here is What to Know Beyond Why DexCom, Inc. (DXCM) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

DexCom (DXCM) Launches One+ Real-time CGM System in Europe

by Zacks Equity Research

DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.

Curious about DexCom (DXCM) Q4 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.

Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.

DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the closing of the recent trading day, DexCom (DXCM) stood at $121.35, denoting a +0.46% change from the preceding trading day.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed at $124.25 in the latest trading session, marking a +1.88% move from the prior day.

Intuitive Surgical (ISRG) Seeks FDA Nod for Next-Gen da Vinci 5

by Zacks Equity Research

Intuitive Surgical (ISRG) aims to boost its da Vinci portfolio with the addition of its next-generation da Vinci 5 multiport surgical robot.

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

DexCom (DXCM) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

DexCom (DXCM) concluded the recent trading session at $127.12, signifying a -1.68% move from its prior day's close.

If You Invested $1000 in DexCom 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA

by Zacks Equity Research

Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

DexCom's (DXCM) G7 Links With Tandem's Insulin Pump in Europe

by Zacks Equity Research

Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.